Endpoints Shorts: Dr. Nadia Sethi on Novartis Pharmaceuticals' BLZ945 - Endpoints

Welcome to the latest episode of Endpoints Shorts, presented by the ALS Therapy Development Institute. I’m Jonathan Gang. In these bite-size podcasts, we’ll be tackling important scientific concepts for people interested in ALS research, current clinical trials, and news from around the ALS space – all in 15 minutes or less. Our guide throughout this series will be Dr. Nadia Sethi, ALS TDI’s Director of Community Outreach and Engagement. Today, Nadia joins us to talk about Novartis Pharmaceuticals’ phase 2 trial for BLZ945.<a href="https://www.als.net/donate/" rel="payment">Support the show: https://www.als.net/donate/</a>See <a href="https://omnystudio.com/listener">omnystudio.com/listener</a> for privacy information.